Dhanuka Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dhanuka Laboratories Limited, the promoter of Orchid Pharma, has submitted its annual declaration under SEBI Takeover Regulations confirming that it and persons acting in concert have not created any new encumbrance (pledge or charge) on Orchid Pharma shares during FY 2024-25. Any existing encumbrances were already disclosed earlier. This is a routine yearly compliance filing required from promoters regarding pledging activity. The declaration is essentially a 'nil' report on new encumbrances for the fiscal year.
Neutral for shareholders — the promoter has not pledged any additional shares or created new charges during the year, indicating no incremental financial stress or fundraising via share pledges. No direct impact on stock price expected from this routine compliance filing.